Hormone Related Cancers Program

激素相关癌症计划

• 批准号: 10267042
• 负责人: STUART S MARTIN
• 金额: $ 3.96万
• 依托单位: UNIVERSITY OF MARYLAND BALTIMORE
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-08-08 至 2026-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10267042
• 关键词: Address; Advanced Malignant Neoplasm; Affect; African American; Aromatase Inhibitors; Baltimore; Basic Science; Biology; Biometry; Breast cancer metastasis; Catchment Area; Cigarette; Clinical Research; Clinical Trials; Collaborations; Community Outreach; Comprehensive Cancer Center; County; Development; Diagnosis; Doctor of Medicine; Doctor of Philosophy; Enrollment; Flow Cytometry; Funding; Funding Agency; Genomics; Goals; Grant; Hormones; Human; Image; Institutes; Interdisciplinary Study; Intervention Trial; Investigational Therapies; Laboratories; Malignant Neoplasms; Malignant neoplasm of ovary; Malignant neoplasm of prostate; Maryland; Mediating; Medical; Medical center; Mission; Molecular Biology; Morbidity - disease rate; NCI Center for Cancer Research; Neoplasm Metastasis; Pathology; Patients; Peer Review; Pharmaceutical Preparations; Pharmacy Schools; Phase III Clinical Trials; Physiology; Population; Population Sciences; Public Health Schools; Publications; Recommendation; Recurrence; Research; Research Personnel; Research Priority; Resistance; Resistance development; Resources; School Dentistry; Services; Source; System; Therapeutic Intervention; Tissues; Translational Research; Underrepresented Minority; Universities; Work; acronyms; anticancer research; biobank; cancer health disparity; cancer imaging; cancer recurrence; cancer stem cell; cancer therapy; college; community engagement; demographics; disparity reduction; hormone related cancer; hormone therapy; improved; malignant breast neoplasm; medical schools; member; mortality; neoplasm immunotherapy; new technology; precision medicine; professor; programs; recruit; response; structural biology; targeted treatment; therapeutic target; treatment response; tumor; tumor immunology; virology

11.0 Abstract: Hormone Related Cancers (HRC) Program The overarching goal of the HRC Program at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) is to reduce the morbidity and mortality of cancers that arise from hormone-related tissues. To achieve this mission, the program focuses on three specific aims: Aim 1: Identify targets in hormone-related cancers that mediate innate and acquired resistance improves the understanding of how cancers resist hormonal therapies or develop resistance during recurrence; Aim 2: Target mechanisms that regulate cancer stem cells and promote metastasis, with a focus on defining and therapeutically targeting mechanisms of cancer recurrence; and Aim 3: Develop strategies to improve diagnosis, inform treatment, and evaluate treatment response to apply new technologies that advance cancer imaging and accelerate analysis of tumor drug response for precision medicine. To achieve these three aims, HRC members are supported by collaborators and resources throughout other UMGCCC programs as well as exceptional shared services. The HRC Program has 46 members, including 30 full members and 16 associate members, who conduct basic, translational, and clinical research chiefly in breast, prostate, and ovarian cancer with $8.7 million direct annual funding ($11.0 million total), including $3.4 million (39%) from NCI and $2.6 million from other peer-reviewed sources. HRC Program members receive $2.7 million annually from non–peer-reviewed funding sources. During this funding period, HRC members authored 506 cancer-related publications, of which 17% resulted from intraprogrammatic, 28% from interprogrammatic, 6% from intra and interprogrammatic collaborations; and 60% of publications include collaborations with external investigators, reflecting the high national impact of the HRC Program. HRC Program members manage numerous clinical trials. During this grant period, the HRC Program enrolled 1,412 patients on clinical trials, including 213 on interventional trials (200 therapeutic interventional), and 1,199 patients on non-interventional trials. 41.5% of patients were underrepresented minorities, reflecting the demographics of the catchment area. The research programs of HRC members utilize all of the UMGCCC shared services. The HRC Program collaborates with the other four UMGCCC Research Programs and engages community outreach and engagement to identify and address the cancer research priorities of the catchment area.

11.0摘要：激素相关癌症(HRC)计划 马里兰大学马琳分校和斯图尔特·格林鲍姆分校人权委员会项目的总体目标 综合癌症中心(UMGCCC)旨在降低因以下原因引起的癌症的发病率和死亡率 荷尔蒙相关组织。为实现这一使命，该方案侧重于三个具体目标：目标1：确定 激素相关癌症中介导先天和获得性耐药的靶点改善了 了解癌症如何抵抗激素治疗或在复发过程中产生抵抗；目标2：靶点 调节癌症干细胞和促进转移的机制，重点是定义和 癌症复发的治疗靶向机制；以及目标3：制定策略以改善 诊断、告知治疗和评估治疗反应，以应用先进的新技术 肿瘤成像和加速分析肿瘤药物反应，用于精准医学。要做到这三点 AIMS，HRC成员在其他UMGCCC计划中得到合作者和资源的支持，如 以及卓越的共享服务。人权委员会计划有46名成员，其中30名是正式成员，16名是正式成员 准会员，主要从事基础、翻译和临床研究，包括乳房、前列腺和 卵巢癌，每年直接资助870万美元(总计1100万美元)，其中包括来自NCI的340万美元(39%) 以及来自其他同行审查来源的260万美元。人权委员会计划成员每年从以下机构获得270万美元 未经同行审查的资金来源。在这一资助期间，人权委员会成员撰写了506项与癌症有关的 出版物，其中17%来自方案内，28%来自方案间，6%来自方案内和 方案间协作；60%的出版物包括与外部调查人员的协作， 反映了人权委员会方案在全国范围内的巨大影响。HRC计划成员管理着众多的临床 审判。在这一赠款期间，HRC方案招募了1,412名患者进行临床试验，其中包括213名 干预性试验(200项治疗干预性试验)，以及1199名非干预性试验患者。41.5% 患者是代表不足的少数民族，反映了集水区的人口结构。这项研究 人权委员会成员的计划利用了UMGCCC的所有共享服务。人权理事会计划与 其他四个UMGCCC研究计划，并参与社区外展和参与，以确定和 解决集水区癌症研究的优先事项。